Kangstem Biotech Receives Phase 1/2a Clinical Trial CSR for Knee Osteoarthritis Treatment 'FURESTEM-OA Kit Inj.'... Share Price at 1,934 Won
Kangstem Biotech announced in a regulatory filing that it has received the clinical study report (CSR) for its domestic Phase 1/2a clinical trial of 'FURESTEM-OA Kit Inj.,' a candidate treatment for knee osteoarthritis. The share price rose 100 won to 1,934 won. The clinical trial was conducted to

Kangstem Biotech announced in a regulatory filing that it has received the clinical study report (CSR) for its domestic Phase 1/2a clinical trial of 'FURESTEM-OA Kit Inj.,' a candidate treatment for knee osteoarthritis. The share price rose 100 won to 1,934 won.
The clinical trial was conducted to evaluate the safety and exploratory efficacy of FURESTEM-OA Kit Inj. when administered to patients with knee osteoarthritis. The trial was designed as a single-dose, stepwise dose-escalation, and optimal dose-finding study, and was carried out at seven domestic institutions, including Kyung Hee University Hospital.
Regarding the timeline, Kangstem Biotech applied for the clinical trial on December 10, 2024, and received approval from the Ministry of Food and Drug Safety on January 24, 2025.
With the receipt of this study report, attention is focused on the specific safety and efficacy evaluation results. However, the confirmed disclosure does not include detailed evaluation figures or clinical trial results, making it difficult to conclude the treatment's effectiveness.
The company explained through investment cautionary notes related to the clinical trial that the probability of an investigational drug ultimately receiving drug approval is statistically known to be around 10%. It also stated that results during the clinical trial and product approval process may fall short of expectations, and that the commercialization plan may accordingly be changed or abandoned.
Going forward, the safety and exploratory efficacy evaluation results contained in the study report, as well as the direction of subsequent development, are expected to emerge as key points of interest.
[This article is provided for informational purposes for investment reference and does not recommend the purchase or sale of any specific stock. Content may vary depending on market conditions. Investment decisions and their consequences are the responsibility of the investor. AI provided partial assistance.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.


